Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa.
BACKGROUND
Herpes simplex virus type 2 (HSV-2) infection increases acquisition and transmission of HIV, but the results of trials measuring the impact of HSV-2 therapy on HIV genital shedding and HIV acquisition are mixed, and the potential impact of HSV-2 therapy on the incidence of HIV at the population level is unknown.


METHODS
The effects of episodic and suppressive HSV-2 therapy were simulated using the individual-level model STDSIM fitted to data from Cotonou, Benin (relatively low HIV prevalence) and Kisumu, Kenya (high HIV prevalence). Clinician- and patient-initiated episodic therapy, started when symptomatic, were assumed to reduce ulcer duration. Suppressive therapy, given regardless of symptoms, was also assumed to reduce ulcer frequency and HSV-2 infectiousness.


RESULTS
Clinician-initiated episodic therapy in the general population had almost no effect on the incidence of HIV. The impact of patient-initiated therapy was higher because of earlier treatment initiation, but still low (<5%) unless symptom recognition and treatment-seeking behaviour were very high. Suppressive therapy given to female sex workers (FSW) in Kisumu had little effect on population HIV incidence. In Cotonou, suppressive therapy in FSW with high coverage and long duration reduced population HIV incidence by >20% in the long term. Impact was increased in both cities by also treating a proportion of their clients. Long-term suppressive therapy with high coverage in the general population could reduce HIV incidence by more than 30%.


CONCLUSIONS
These results show that HSV-2 therapy could potentially have a population-level impact on the incidence of HIV, especially in more concentrated epidemics. However, a substantial impact requires high coverage and long duration therapy, or very high symptom recognition and treatment-seeking behaviour.
White
R G
RG
Infectious Disease Epidemiology Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. richard.white@lshtm.ac.uk
Freeman
E E
EE
Orroth
K K
KK
Bakker
R
R
Weiss
H A
HA
O'Farrell
N
N
Buvé
A
A
Hayes
R J
RJ
Glynn
J R
JR
D000293:Adolescent; D000328:Adult; D017954:Africa South of the Sahara / Q000453:epidemiology; D017677:Age Distribution; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000453:epidemiology* / Q000517:prevention & control; D015497:HIV-1; D006558:Herpes Genitalis / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology*; D018258:Herpesvirus 2, Human; D006801:Humans; D015994:Incidence; D008297:Male; D015995:Prevalence
Sex Transm Dis. 2002 Apr;29(4):228-38
11912465
J Infect Dis. 2000 Oct;182(4):1090-6
10979904
J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):121-4
12794542
J Infect Dis. 2008 Dec 15;198(12):1804-8
18928378
J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):346-53
18176323
J Infect Dis. 2005 Feb 1;191 Suppl 1:S107-14
15627220
Epidemiol Infect. 2008 Apr;136(4):551-61
17559692
AIDS. 2006 Jan 2;20(1):73-83
16327322
Lancet. 2008 Jun 21;371(9630):2109-19
18572080
J Infect Dis. 2005 Feb 1;191 Suppl 1:S168-78
15627227
AIDS. 2001 Aug;15 Suppl 4:S97-108
11686471
Sex Transm Infect. 2002 Apr;78 Suppl 1:i55-63
12083448
AIDS. 2001 Aug;15 Suppl 4:S117-26
11686460
Sex Transm Infect. 2007 Aug;83 Suppl 1:i17-24
17405782
J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):435-45
15021308
Sex Transm Dis. 2006 Sep;33(9):536-44
16778738
Sex Transm Infect. 2007 Aug;83 Suppl 1:i5-16
17405781
AIDS. 2008 Sep 12;22(14):1841-50
18753931
JAMA. 1998 Jul 1;280(1):61-6
9660365
J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):77-83
18667923
AIDS. 2002 Dec 6;16(18):2425-30
12461416
AIDS. 2001 Aug;15 Suppl 4:S5-14
11686465
J Acquir Immune Defic Syndr. 2004 Dec 1;37(4):1500-13
15602129
J Infect Dis. 2007 Nov 15;196(10):1500-8
18008230
Bull World Health Organ. 2004 Jun;82(6):447-53
15356938
AIDS. 1999 Mar 11;13(4):536-7
10197391
AIDS. 2006 Jan 9;20(2):261-7
16511420
Drugs. 1996 Nov;52(5):754-72
9118821
AIDS. 2000 Mar 31;14(5):573-93
10780720
N Engl J Med. 2007 Feb 22;356(8):790-9
17314338
J Infect Dis. 2002 Jan 1;185(1):45-52
11756980
J Infect Dis. 1999 Jan;179(1):16-24
9841817
J Infect Dis. 1999 Nov;180(5):1459-65
10515804
Ann Intern Med. 1989 Jun 1;110(11):882-7
2541645
Clin Infect Dis. 2004 Nov 1;39 Suppl 5:S240-7
15494895
AIDS. 2007 Jul 31;21(12):1569-78
17630552
J Infect Dis. 2002 Dec 15;186(12):1718-25
12447756
J Infect Dis. 2003 Nov 15;188(10):1492-7
14624374
Lancet. 2001 Apr 14;357(9263):1149-53
11323041
AIDS. 1998 Oct 1;12(14):1889-98
9792390
J Infect Dis. 1998 Dec;178(6):1616-22
9815213